BNTC News and Press, Benitec Biopharma Inc.

2026-05-14 08:05:26 ET More on Benitec Seeking Alpha’s Quant Rating on Benitec Historical earnings data for Benitec Financial information for Benitec Read the full article on Seeking Alpha For further details see: Benitec GAAP EPS of -$0.24...

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with hi...

-  Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - &...

HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace...

- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvemen...

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reporte...

Air Canada Inc. (ACDVF) is expected to report $0.2 for Q4 2025 Edesa Biotech Inc. (EDSA) is expected to report $-0.28 for Q1 2026 Advance Auto Parts Inc. (AAP) is expected to report $0.41 for Q4 2025 Neuphoria Therapeutics Inc. (NEUP) is expected to report $-0.56 for Q2 2026 Kirin...

2026-02-12 08:54:13 ET More on Benitec Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade Benitec GAAP EPS of -$0.22 Seeking Alpha’s Quant Rating on Benitec Historical earnings data for Benitec Financial inf...

- The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of C...

2026-01-31 04:39:28 ET ... Read the full article on Seeking Alpha For further details see: Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade